These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 29117285)

  • 1. Topical Timolol for Paronychia and Pseudopyogenic Granuloma in Patients Treated With Epidermal Growth Factor Receptor Inhibitors and Capecitabine.
    Cubiró X; Planas-Ciudad S; Garcia-Muret MP; Puig L
    JAMA Dermatol; 2018 Jan; 154(1):99-100. PubMed ID: 29117285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of paronychia with pseudopyogenic granulomas secondary to epidermal growth factor receptor inhibitors: An assessment of topical timolol and the need for multiple medical and procedural therapies.
    Olamiju B; Bhullar S; Coleman EL; Leventhal JS
    J Am Acad Dermatol; 2021 Mar; 84(3):806-808. PubMed ID: 32526318
    [No Abstract]   [Full Text] [Related]  

  • 3. Combination of available topical beta-blockers and antibiotic ointment for epidermal growth factor receptor tyrosine kinase inhibitor-induced paronychia and pseudopyogenic granulomas in Taiwan.
    Liu HL; Chuang CH; Chen CL; Wei PJ; Yang CJ
    J Oncol Pharm Pract; 2023 Sep; 29(6):1374-1380. PubMed ID: 36112905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recalcitrant trametinib-induced paronychia treated successfully with topical timolol in a pediatric patient.
    Martínez-de-Espronceda I; Bernabeu-Wittel J; Azcona M; Monserrat MT
    Dermatol Ther; 2020 Jan; 33(1):e13164. PubMed ID: 31705590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical betaxolol for treating relapsing paronychia with pyogenic granuloma-like lesions induced by epidermal growth factor receptor inhibitors.
    Yen CF; Hsu CK; Lu CW
    J Am Acad Dermatol; 2018 Jun; 78(6):e143-e144. PubMed ID: 29339238
    [No Abstract]   [Full Text] [Related]  

  • 6. Successful management of angiolymphoid hyperplasia with eosinophilia in a split-face trial of topical tacrolimus and timolol solution.
    Chacon A; Mercer J
    G Ital Dermatol Venereol; 2016 Aug; 151(4):436-40. PubMed ID: 25014586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are topical beta-blockers really effective "in real life" for targeted therapy-induced paronychia.
    Sibaud V; Casassa E; D'Andrea M
    Support Care Cancer; 2019 Jul; 27(7):2341-2343. PubMed ID: 30847700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of epidermal growth factor receptor inhibitor-induced severe paronychia with pyogenic granuloma-like lesions with topical betaxolol: an open-label observation study.
    Yen CF; Hsu CK; Yang HS; Lee CN; Chi CC; Chung WH; Wang CL; Pang JS; Wang CW; Ko YS; Lu CW
    Int J Dermatol; 2020 Mar; 59(3):326-332. PubMed ID: 31763692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. When side effect becomes the effect: Efficacy of capecitabine in refractory psoriasis.
    Karakas Y; Vural S; Diker O; Dizdar O
    Dermatol Ther; 2018 Nov; 31(6):e12629. PubMed ID: 30230162
    [No Abstract]   [Full Text] [Related]  

  • 10. Capecitabine Toxicity and Dihydropyrimidine Dehydrogenase Deficiency.
    Tariq Z; Mudge R; Phillips S
    Am J Ther; 2018; 25(6):e742-e743. PubMed ID: 29889674
    [No Abstract]   [Full Text] [Related]  

  • 11. [Topical steroids in the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab].
    Coquart N; Karam A; Metges JP; Misery L
    Ann Dermatol Venereol; 2010 Apr; 137(4):306-7. PubMed ID: 20417368
    [No Abstract]   [Full Text] [Related]  

  • 12. Capecitabine-Induced Severe Toxicity Secondary to DPD Deficiency and Successful Treatment with Low Dose 5-Fluorouracil.
    Kodali S; Bathini V; Rava P; Tipirneni E
    J Gastrointest Cancer; 2017 Mar; 48(1):66-69. PubMed ID: 26744322
    [No Abstract]   [Full Text] [Related]  

  • 13. Report of two cases of acute cardiac adverse events in patients with colorectal carcinoma receiving oral capecitabine.
    Lampropoulos S; Roditis P; Koulouris E; Zafiris A; Tzimou M; Kyratlidis K; Pavlidis K; Godwin SA; Kosmas C
    Anticancer Drugs; 2017 Aug; 28(7):801-807. PubMed ID: 28489615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unusual scrotal and penile ulcerations together with palmar-plantar erythrodysesthesia syndrome in a patient with metastatic colon carcinoma treated with capecitabine.
    Ljubojevic Hadzavdic S; Stulhofer Buzina D; Murtezani I; Skerlev M
    J Eur Acad Dermatol Venereol; 2017 Jun; 31(6):e304-e306. PubMed ID: 27987319
    [No Abstract]   [Full Text] [Related]  

  • 15. [Hepatic toxicity in HER-2(+) breast cancer patient under treatment with capecitabine and lapatinib].
    Romero Carreño E; Marcos Rodríguez JA; Santana Martínez S; de la Cruz Merino L
    Farm Hosp; 2016 Mar; 40(2):134-6. PubMed ID: 26980172
    [No Abstract]   [Full Text] [Related]  

  • 16. Adherence and safety study in patients on treatment with capecitabine.
    Fernández-Ribeiro F; Olivera-Fernández R; Crespo-Diz C
    Farm Hosp; 2017 Mar; 41(2):204-221. PubMed ID: 28236798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study.
    Casadei Gardini A; Foca F; Scartozzi M; Silvestris N; Tamburini E; Faloppi L; Brunetti O; Rudnas B; Pisconti S; Valgiusti M; Marisi G; Foschi FG; Ercolani G; Tassinari D; Cascinu S; Frassineti GL
    Sci Rep; 2017 Feb; 7():42499. PubMed ID: 28211921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: a retrospective analysis in Chinese postmenopausal women.
    Su J; Lai J; Yang R; Xu B; Zhu Y; Zhao M; Yang C; Liang G
    BMC Gastroenterol; 2019 Jan; 19(1):17. PubMed ID: 30683047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer.
    Suto T; Ishiguro M; Hamada C; Kunieda K; Masuko H; Kondo K; Ishida H; Nishimura G; Sasaki K; Morita T; Hazama S; Maeda K; Mishima H; Ike H; Sadahiro S; Sugihara K; Okajima M; Saji S; Sakamoto J; Tomita N
    Int J Clin Oncol; 2017 Jun; 22(3):494-504. PubMed ID: 28078540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
    Masuda N; Lee SJ; Ohtani S; Im YH; Lee ES; Yokota I; Kuroi K; Im SA; Park BW; Kim SB; Yanagita Y; Ohno S; Takao S; Aogi K; Iwata H; Jeong J; Kim A; Park KH; Sasano H; Ohashi Y; Toi M
    N Engl J Med; 2017 Jun; 376(22):2147-2159. PubMed ID: 28564564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.